Journal of Clinical Endocrinology & Metabolism, Vol 79, 32-38, Copyright © 1994 by Endocrine Society

ARTICLES

No alteration in the primary structure of the mineralocorticoid receptor in a family with pseudohypoaldosteronism

MC Zennaro, P Borensztein, X Jeunemaitre, D Armanini and F Soubrier
INSERM U-36, College de France, Paris.

We have studied the molecular structure of the mineralocorticoid receptor (MR) complementary DNA (cDNA) in a kindred affected by pseudohypoaldosteronism (PHA). In this family, the clinical symptoms included salt wasting and failure to thrive, accompanied by high urinary levels of sodium despite hyponatremia, hyperkalemia and metabolic acidosis, elevation of PRA, and high plasma aldosterone levels. The patients were resistant to mineralocorticoid administration, but their symptoms ameliorated after a period of sodium supplementation, which was discontinued in older patients. Binding studies performed on mononuclear leukocytes of the members of the family have shown the absence of MR in two siblings and a marked reduction in another sibling of the father, suggesting either the absence of MR or a defect of the ligand-binding domain of the MR in these patients. Southern analysis of patient's DNA did not show any major rearrangement of the MR gene. To search for point mutations in the cDNA of the MR, we performed amplification of the MR cDNA by the polymerase chain reaction and direct sequencing of amplified products. No mutation was found in the entire coding sequence of the MR in patients affected by PHA. Although these results do not exclude a molecular abnormality present on the MR gene, they indicate that PHA in this family is not related to a modification of the MR primary structure.

This article has been cited by other articles:

				A. Balsamo, A. Cicognani, M. Gennari, W. G Sippell, S. Menabo, F. Baronio, and F. G Riepe Functional characterization of naturally occurring NR3C2 gene mutations in Italian patients suffering from pseudohypoaldosteronism type 1 Eur. J. Endocrinol., February 1, 2007; 156(2): 249 - 256. [Abstract] [Full Text] [PDF]

				D. S. Geller, J. Zhang, M.-C. Zennaro, A. Vallo-Boado, J. Rodriguez-Soriano, L. Furu, R. Haws, D. Metzger, B. Botelho, L. Karaviti, et al. Autosomal Dominant Pseudohypoaldosteronism Type 1: Mechanisms, Evidence for Neonatal Lethality, and Phenotypic Expression in Adults J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1429 - 1436. [Abstract] [Full Text] [PDF]

				A.-M. Nystrom, M.-L. Bondeson, N. Skanke, J. Martensson, B. Stromberg, J. Gustafsson, and G. Anneren A Novel Nonsense Mutation of the Mineralocorticoid Receptor Gene in a Swedish Family with Pseudohypoaldosteronism Type I (PHA1) J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 227 - 231. [Abstract] [Full Text] [PDF]

				F. G. Riepe, N. Krone, M. Morlot, M. Ludwig, W. G. Sippell, and C.-J. Partsch Identification of a Novel Mutation in the Human Mineralocorticoid Receptor Gene in a German Family with Autosomal-Dominant Pseudohypoaldosteronism Type 1: Further Evidence for Marked Interindividual Clinical Heterogeneity J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1683 - 1686. [Abstract] [Full Text] [PDF]

				M. Viemann, M. Peter, J. P. López-Siguero, G. Simic-Schleicher, and W. G. Sippell Evidence for Genetic Heterogeneity of Pseudohypoaldosteronism Type 1: Identification of a Novel Mutation in the Human Mineralocorticoid Receptor in one Sporadic Case and No Mutations in Two Autosomal Dominant Kindreds J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2056 - 2059. [Abstract] [Full Text]

				K. Arai, K. Zachman, T. Shibasaki, and G. P. Chrousos Polymorphisms of Amiloride-Sensitive Sodium Channel Subunits in Five Sporadic Cases of Pseudohypoaldosteronism: Do They Have Pathologic Potential? J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2434 - 2437. [Abstract] [Full Text]

				M.-C. Zennaro, N. Farman, J.-P. Bonvalet, and M. Lombes Tissue-Specific Expression of {alpha} and {beta} Messenger Ribonucleic Acid Isoforms of the Human Mineralocorticoid Receptor in Normal and Pathological States J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1345 - 1352. [Abstract] [Full Text] [PDF]

				F. Gamarra, G. Simic-Schleicher, R. M. Huber, A. Ulsenheimer, P. C. Scriba, U. Kuhnle, and M. Wehling Impaired Rapid Mineralocorticoid Action on Free Intracellular Calcium in Pseudohypoaldosteronism J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 831 - 834. [Abstract] [Full Text] [PDF]

				A. Kralli and K. R. Yamamoto An FK506-sensitive Transporter Selectively Decreases Intracellular Levels and Potency of Steroid Hormones J. Biol. Chem., July 19, 1996; 271(29): 17152 - 17156. [Abstract] [Full Text] [PDF]

				M.-C. Zennaro, M.-C. Keightley, Y. Kotelevtsev, G. S. Conway, F. Soubrier, and , P. J. Fuller Human Mineralocorticoid Receptor Genomic Structure and Identification of Expressed Isoforms J. Biol. Chem., September 8, 1995; 270(36): 21016 - 21020. [Abstract] [Full Text] [PDF]